K. De et al. / Tetrahedron 64 (2008) 10497–10500
10499
3.2. General procedure for the synthesis of 2,3-unsaturated-
O-glycosides in HFIP
2.40 (t, J¼1.8 Hz, 1H, –ChCH), 3.99–4.06 (m, 1H, H-5), 4.15 (dd,
J¼5.1, 12 Hz, 2H, Ha-6, Hb-6), 4.25 (d, J¼2.4 Hz, 2H, Ha-10, Hb-10),
5.18 (br s, 1H, H-1), 5.27 (dd, J¼9.6,1.5 Hz, 1H, H-4), 5.75–5.88 (m,
To a stirred mixture of 3,4,6-tri-O-acetyl-
D-glucal (0.184 mmol,
2H, H-2, H-3); 13C NMR (75 MHz, CDCl3):
d 20.8, 21.0, 55.1, 62.8,
50 mg) in HFIP (0.5 mL) was added the alcohol (10 equiv) and the
reaction mixture was heated at reflux (60 ꢀC). After 12 h stirring,
the reaction was complete (TLC monitoring). Then HFIP was
evaporated under vacuum and the product was purified by column
chromatography using cyclohexane/ethyl acetate (cyclohexane/
AcOEt 90:10) as eluent.
65.2, 67.2, 74.9, 79.1, 92.8,127.3, 129.8,170.2,170.8; ESI m/z (rel int.):
291.2 [MþNa]þ (100).
3.2.7. Benzyl 4,6-di-O-acetyl-2,3-dideoxy-a-D-erythro-hex-2-
enopyranoside (2g)13
Colourless oil; [
a
]
150 (c 0.8, MeOH); 1H NMR (300 MHz,
D
CDCl3): 2.01 (s, 3H, –OCOCH3), 2.03 (s, 3H, –OCOCH3), 4.00–4.24
d
3.2.1. Hexafluoroisopropyl 4,6-di-O-acetyl-2,3-dideoxy-
a
-
D
-
(m, 3H, H-5, Ha-6, Hb-6), 4.53 (d, J¼12 Hz, 1H, –O–HCH–Ph), 4.74
(d, J¼12 Hz, 1H, –O–HCH–Ph), 5.06 (br s, 1H, H-1), 5.27 (dd, J¼9.6,
1.2 Hz, 1H, H-4), 5.79–5.85 (m, 2H, H-2, H-3), 7.27–7.30 (m, 5H, Ph);
erythro-hex-2-enopyranoside (2a)9
White oil; [
2.07 (s, 3H, –CO–CH3), 2.09 (s, 3H, –CO–CH3), 3.98–4.06 (m, 1H, H-
a]
D 208.2 (c 0.8, MeOH); 1H NMR (200 MHz, CDCl3):
d
13C NMR (75 MHz, CDCl3):
d 20.9, 21.0, 62.9, 65.3, 67.1, 67.3, 93.6,
5), 4.15 (d, J¼4 Hz, 2H, H-6), 4.51 (sept, J¼6 Hz), 5.22 (br s, 1H, H-1),
127.8, 127.9, 128.0, 128.5, 129.4, 138.2, 170.3, 170.9; ESI m/z (rel int.):
5.29 (dd, J¼9.6, 1.6 Hz, 1H, H-4), 5.79 (ddd, J¼2, 2.4, 10.2 Hz, 1H,
344.3 [MþNa]þ (100).
H-2), 5.95–5.99 (d, J¼10.4 Hz); 13C NMR (75 MHz, CDCl3):
d 20.7,
20.9, 62.2, 64.6, 68.1, 72 (sept, J¼33 Hz), 121.2 (q, J¼283 Hz), 121.7
3.2.8. Phenyl 4,6-di-O-acetyl-2,3-dideoxy-
a
-
D
-erythro-hex-2-
White solid, mp 50 ꢀC (lit. 47–48 ꢀC); [
a] 102 (c 0.65, MeOH);
D
(q, J¼284 Hz), 125, 131.5, 170.1, 170.6; 19F NMR (188 MHz, CDCl3):
enopyranoside (2h)13
d
ꢁ74.2 (m, 3F), ꢁ74.0 (m, 3F). Anal. calcd for C13H14F6O6: C 41.06, H
3.71; found: C 41.30, H 3.85.
1H NMR (300 MHz, CDCl3):
d 1.91 (s, 3H, –OCOCH3), 2.04 (s, 3H,
–OCOCH3), 4.05–4.25 (m, 3H, H-5, Ha-6, Hb-6), 5.31 (d, J¼9 Hz, 1H,
3.2.2. Ethyl 4,6-di-O-acetyl-2,3-dideoxy-
a
-
D
-erythro-hex-2-
H-4), 5.63 (br s, 1H, H-1), 5.94–5.98 (m, 2H, H-2, H-3), 6.94–7.05 (m,
enopyranoside (2b)13
3H, Ph), 7.19–7.26 (m, 2H, Ph); 13C NMR (75 MHz, CDCl3):
d 20.7,
White oil; [
a
]
120 (c 1.2, MeOH); 1H NMR (300 MHz, CDCl3):
21.0, 62.6, 65.0, 67.8, 92.9,117.0,122.5,127.1,129.5,130.1,157.1,170.3,
D
d
1.25 (t, J¼7.2 Hz, 3H, –O–CH2–CH3), 2.11 (s, 3H, –CO–CH3), 2.12 (s,
170.8; ESI m/z (rel int.): 329.3 [MþNa]þ (100).
3H, –CO–CH3), 3.58–3.63 (m, 1H, –O–HCH–CH3), 3.83–3.88 (m, 1H,
–O–HCH–CH3), 4.12–4.31 (m, 3H, H-5, Ha-6, Hb-6), 5.07 (s,1H, H-1),
5.34 (dd, J¼1.2, 9.6 Hz, 1H, H-4), 5.84–5.98 (m, 2H, H-2, H-3); 13C
3.2.9. p-Methoxyphenyl 4,6-di-O-acetyl-2,3-dideoxy-a-D-erythro-
hex-2-enopyranoside (2i)13
NMR (75 MHz, CDCl3):
d
15.3, 20.7, 20.9, 63.0, 64.3, 65.3, 66.8, 94.5,
White solid, mp 69 ꢀC (lit. 69–70 ꢀC); [
a
]
D 104 (c 1.4, MeOH); 1H
NMR (300 MHz, CDCl3): d 1.95 (s, 3H, –OCOCH3), 2.04 (s, 3H,
128.0, 129.0, 170.3, 170.7; ESI m/z (rel int.): 281.2 [MþNa]þ (100).
–OCOCH3), 3.69 (s, 3H, –OCH3), 4.07–4.21 (m, 3H, H-5, Ha-6, Hb-6),
5.29 (d, J¼9.0 Hz, 1H, H-4), 5.49 (br s, 1H, H-1), 5.93 (br s, 2H, H-2,
H-3), 6.75 (dd, J¼9.0 Hz, 2H, Ph), 6.97 (dd, J¼9 Hz, 2H, Ph); 13C NMR
3.2.3. Methyl 4,6-di-O-acetyl-2,3-dideoxy-a-D-erythro-hex-2-
enopyranoside (2c)14
Colourless oil; [
a
]D 124 (c 1.2, MeOH); 1H NMR (300 MHz, CDCl3):
(75 MHz, CDCl3): d 20.8, 21.0, 55.7, 62.8, 65.2, 67.7, 94.1, 114.6, 118.7,
d
2.02 (s, 3H, –OCOCH3), 2.04 (s, 3H, –OCOCH3), 3.39 (s, 3H, OCH3),
127.3, 130.0, 151.2, 155.3, 170.3, 170.8; ESI m/z (rel int.): 359.1
3.96–4.04 (m, 1H, H-5), 4.13–4.19 (m, 2H, H-6a, H-6b), 4.86 (br s,1H,
H-1), 5.25 (dd, J¼9.0, 1.57 Hz, 1H, H-4), 5.77–5.91 (m, 2H, H-2, H-3);
13C NMR (75 MHz, CDCl3): 20.8, 21.0, 56.0, 63.0, 65.3, 66.9, 95.5,
127.7, 129.3, 170.3, 170.8; ESI m/z (rel int.): 267.1 [MþNa]þ (100).
[MþNa]þ (100).
3.2.10. p-Nitrophenyl 4,6-di-O-acetyl-2,3-dideoxy-a-D-erythro-
hex-2-enopyranoside (2j)13
White solid, mp 90 ꢀC (lit. 94–95 ꢀC); [
a]
D 170 (c 0.6, MeOH); 1H
NMR (300 MHz, CDCl3): d 1.89 (s, 3H, –OCOCH3), 2.05 (s, 3H,
3.2.4. Isopropyl 4,6-di-O-acetyl-2,3-dideoxy-
a
-D-erythro-hex-2-
enopyranoside (2d)15
–OCOCH3), 4.05–4.23 (m, 3H, H-5, Ha-6, Hb-6), 5.34 (dd, J¼9.6,
1.2 Hz, 1H, H-4), 5.74 (br s, 1H, H-1), 5.93 (dd, J¼1.8, 10.2 Hz, 1H,
H-3), 6.04 (d, J¼10.2 Hz, 1H, H-2), 7.11 (d, J¼9.0 Hz, 2H, Ph), 8.15 (d,
Colourless oil; [a]
D 97 (c 0.7, MeOH); 1H NMR (300 MHz, CDCl3):
1.11 (d, J¼6.3 Hz, 3H, –O–CH(CH3)CH3), 1.18 (d, J¼6.3 Hz, 3H, –O–
d
CH(CH3)CH3), 2.01 (s, 3H, –OCOCH3), 2.02 (s, 3H, –OCOCH3), 3.87
(hept, J¼6.2 Hz, 1H, –O–CH(CH3)CH3), 4.01–4.19 (m, 3H, H-5, Ha-6,
Hb-6), 5.06 (br s, 1H, H-1), 5.23 (dd, J¼9.6, 1.5 Hz, 1H, H-4), 5.70–
J¼9.0 Hz, 2H, Ph); 13C NMR (75 MHz, CDCl3):
d 20.6, 20.9, 62.34,
64.7, 68.4, 92.6, 116.6, 125.7, 125.8, 131.2, 142.6, 161.8, 170.1, 170.5;
ESI m/z (rel int.): 374.2 [MþNa]þ (100).
5.87 (m, 2H, H-2, H-3); 13C NMR (75 MHz, CDCl3):
d 20.8, 21.0,
22.00, 23.5, 63.2, 65.4, 66.8, 70.8, 92.9, 128.5, 128.8, 170.3, 170.8; ESI
3.2.11. Trifluoroethyl 4,6-di-O-acetyl-2,3-dideoxy-a-D-erythro-
m/z (rel int.): 295.2 [MþNa]þ (100).
hex-2-enopyranoside (2k)
Colourless oil; [
d 2.09 (s, 3H), 2.1 (s, 3H), 3.93–4.13 (m, 3H, H-5, OCH2), 4.21–4.23
a]
D 79 (c 0.8, MeOH); 1H NMR (300 MHz, CDCl3):
3.2.5. Allyl 4,6-di-O-acetyl-2,3-dideoxy-
a
-
D
-erythro-hex-2-
enopyranoside (2e)13
(m, 2H, H-6), 5.11 (br s, 1H, H-1), 5.33 (dd, J¼9.6, 1.5 Hz, 1H, H-4),
White oil; [a]
91 (c 0.45, MeOH); 1H NMR (300 MHz, CDCl3):
5.83–5.88 (m, 1H, H-2), 5.96 (d, J¼10.2 Hz, 1H, H-3); 13C NMR
D
d
2.01 (s, 3H, –OCOCH3), 2.03 (s, 3H, –OCOCH3), 3.97–4.25 (m, 5H,
(75 MHz, CDCl3):
d
20.6, 20.9, 62.6, 65.0 (t, J¼34 Hz), 67.5, 94.5,
H-5, Ha-6, Hb-6, Ha-10, Hb-10), 5.01 (br s, 1H, H-1), 5.1–5.27 (m, 3H,
121.9, 123.7 (q, J¼276 Hz), 126.2, 130.4, 170.2, 170.7; 19F NMR
Ha-30, Hb-30, H-4), 5.78–5.94 (m, 3H, H-2, H-3, H-20); 13C NMR
(188 MHz, CDCl3):
d
ꢁ74.64 (t, J¼9 Hz); ESI m/z (rel int.): 335.2
(75 MHz, CDCl3):
d
20.8, 21.0, 63.0, 65.3, 67.0, 69.3, 93.7, 117.6, 127.8,
[MþNa]þ (100).
129.3, 134.1, 170.3, 170.8; ESI m/z (rel int.): 293.2 [MþNa]þ (100).
3.2.12. 2-(N-Benzyloxycarbonylamino)-3-methoxy-
3.2.6. Prop-2-ynyl 4,6-di-O-acetyl-2,3-dideoxy-
a
-
D
-erythro-hex-2-
carbonylethyl 4,6-di-O-acetyl-2,3-dideoxy-a-D-erythro-hex-2-
enopyranoside (2f)14
enopyranoside (2l)13
White solid, mp 59 ꢀC; [
a]
110 (c 0.8, MeOH); 1H NMR
Colourless oil; [
d 2.04 (s, 3H, –OCOCH3), 2.07 (s, 3H, –OCOCH3), 3.76 (s, 3H, –OCH3),
a]
D 46 (c 1.5, MeOH); 1H NMR (200 MHz, CDCl3):
D
(300 MHz, CDCl3):
d
2.02 (s, 3H, –OCOCH3), 2.04 (s, 3H, –OCOCH3),